A new head-to-head analysis is turning heads across the obesity medicine community. A major review has found that retatrutide outperforms tirzepatide (Mounjaro) for weight loss — and by a meaningful margin. The findings have sparked significant conversation among patients, clinicians, and obesity researchers alike, with some already drawing vivid comparisons to capture just how large the gap appears to be.
To understand why this matters, it helps to appreciate what each drug actually does. Tirzepatide is a dual agonist, activating both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Retatrutide goes a step further. It is a triple agonist — activating GLP-1, GIP, and the glucagon receptor simultaneously. This third mechanism, targeting the glucagon receptor to increase energy expenditure and fat oxidation, is widely believed to be the primary reason retatrutide is outpacing its predecessors so dramatically. Patient communities have taken to calling it "triple G" as informal shorthand, reflecting how fundamentally different this drug's mechanism is from earlier GLP-1 medications.
The Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023 (Jastreboff et al.; NCT04881760), enrolled 338 adults with obesity or overweight plus at least one weight-related comorbidity. At 48 weeks, participants on the 12mg dose achieved a mean body weight reduction of approximately 24.2% — with some patients losing 25%, 30%, or more. Critically, 100% of participants in the 8mg group lost at least 5% of their body weight by week 48. These are numbers that simply did not exist in obesity pharmacotherapy before retatrutide entered clinical testing.
Then came TRIUMPH-4. In December 2025, Eli Lilly released Phase 3 data showing a mean weight loss of 28.7% at the 12mg dose over 68 weeks — the highest mean weight loss ever recorded in a Phase 3 obesity trial. That figure is not a ceiling; it is an average.
To appreciate retatrutide's results in context, it is worth reviewing where tirzepatide stands. Tirzepatide has been a genuine breakthrough in obesity treatment. In the landmark SURMOUNT-1 trial, participants on the highest dose of 15mg achieved a mean weight loss of 20.9% over 72 weeks — results that, at the time, were unprecedented for a non-surgical intervention. Tirzepatide can genuinely help patients shed more than a fifth of their body weight after around 17 months of treatment, and many patients have experienced life-changing results.
Tirzepatide is FDA-approved for chronic weight management under the brand name Zepbound, and as a type 2 diabetes medication under the name Mounjaro. It is a meaningful, evidence-based option for millions of patients living with obesity today.
But the data now suggest retatrutide may represent a clear step beyond what tirzepatide can achieve — particularly for patients who need the largest reductions in body weight to meaningfully lower their cardiometabolic risk.
If tirzepatide earned the nickname "King Kong" for its dominance over earlier semaglutide-based treatments, the major review's findings suggest retatrutide — commonly referred to as reta in patient communities — deserves the title of "Godzilla." The nickname captures the scale of the difference: retatrutide does not merely outperform tirzepatide at the margins. The gap is substantial, particularly at higher doses and over longer treatment durations.
Beyond the headline weight loss numbers, retatrutide's Phase 2 data revealed striking improvements in cardiometabolic markers. At 24 weeks, fasting triglycerides fell by approximately 34% in the 12mg group (compared to just 3.1% with placebo). Total cholesterol dropped by 17.3%, and LDL cholesterol declined by approximately 15.6–16.9% in the 8mg groups. Quality of life scores, measured by the SF-36v2, improved across all active dose groups at week 48.
The comparison table below summarizes the key efficacy differences between the two drugs based on available clinical trial data:
| Metric | Tirzepatide (SURMOUNT-1, 15mg) | Retatrutide (TRIUMPH-4, 12mg) |
|---|---|---|
| Mean weight loss | 20.9% | 28.7% |
| Trial duration | 72 weeks | 68 weeks |
| Trial phase | Phase 3 | Phase 3 |
| Receptor targets | GLP-1, GIP | GLP-1, GIP, Glucagon |
| FDA approval status | Approved (Zepbound / Mounjaro) | Not yet approved (NDA not yet filed as of April 2026) |
It is important to note that retatrutide does carry a distinct side effect profile. The most common adverse events observed in Phase 2 were gastrointestinal — nausea, diarrhea, and vomiting — consistent with other GLP-1-based therapies and most prominent during the dose titration phase. A notable finding at higher doses was hyperesthesia and dysesthesia (abnormal skin sensations), reported in 12.9% of the 12mg group in Phase 2, and in 20.9% at 12mg in TRIUMPH-4, compared to 0.7% with placebo. These sensory symptoms are a unique feature of retatrutide's glucagon agonism and are an important part of any informed discussion about this therapy. Discontinuation rates in TRIUMPH-4 were also higher than placebo — 18.2% at the 12mg dose versus 4.0% with placebo — and some discontinuations occurred because participants felt they were losing weight too rapidly.
The phenomenon patients often describe as "food noise" — the persistent, intrusive mental preoccupation with eating — appears to be substantially quieted by retatrutide's triple-receptor mechanism, consistent with the drug's potent appetite-suppressing effects observed across the Phase 2 and Phase 3 data.
This is the question most patients are asking — and the honest answer is that retatrutide's timeline remains uncertain. As of April 2026, Eli Lilly has not yet filed a New Drug Application (NDA) with the FDA for retatrutide, and no FDA approval date has been publicly confirmed. The peer-reviewed Phase 3 publication from TRIUMPH-4 is also still pending. Tirzepatide, by contrast, is already FDA-approved and commercially available. For patients who need treatment today, tirzepatide and semaglutide remain well-established, evidence-based options.
For patients who want to stay informed as retatrutide moves through the regulatory process, glp3md.com exists to provide accurate, peer-reviewed clinical information and maintain a structured waitlist for those who want to be notified as the landscape evolves. Joining the waitlist at glp3md.com is a straightforward way to stay ahead of developments — but it is important to be clear: the waitlist is for informational purposes only. Joining does not guarantee access to medication, a prescription, or any form of treatment. Retatrutide is not FDA-approved, and no promises about medication availability can or should be made. What the waitlist does offer is timely, accurate updates as this remarkable drug moves closer to potential approval — so that patients can have well-informed conversations with their own healthcare providers when the time comes.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.